Leadxpro collaborates with Sanofi on a research project

leadXpro’s team is committed to the application of biophysical and structure-based methods for the discovery and optimization of next-generation lead compounds with unmet efficacy and specificity. The startup specializes in membrane protein targets such as GPCR’s, ion-channels and transporters. leadXpro’s technology platform capitalizes on the expert knowledge regarding membrane protein biochemistry and close collaboration with academic facilities of the Paul Scherrer Institute (PSI) for synchrotron (SLS), X-ray Free Electron Laser (SwissFEL) and the University of Basel (C-CINA) for single particle cryo-electron microscopy (cryo-EM).

Recently, the startup signed a collaboration agreement with Sanofi to combine their structure-based drug discovery efforts and use leadXpro’s single particle cryo-Electron Microscopy (cryo-EM) capabilities for a challenging drug target. In particular, leadXpro will contribute protein sample generation and enable structure determination by high-resolution cryo-electron microscopy to inform about the interaction with small molecule ligands aiming to facilitate the discovery and optimization of novel lead molecules.